Home › Diabetic Eye Problems › Texas › Houston
Diabetic Eye Problems clinical trials in Houston, TX
3 studies for Diabetic Eye Problems are looking for participants at sites in and around Houston (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
RecruitingPhase 3
- Retina Consultants of Texas ( Site 0001), Bellaire · 7 mi away
Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema
RecruitingPhase 2/3
- Retina and Vitreous of Texas /ID# 283051, Bellaire · 7 mi away
A Randomized, Phase 2 Study of Oral BGE-102 in Participants With Center-Involved Diabetic Macular Edema
RecruitingPhase 2
- Site 130, Houston
About Diabetic Eye Problems
Diabetic eye problems such as diabetic retinopathy can harm your vision and sometimes cause blindness. It is important to manage your diabetes and get regular eye exams.
More about Diabetic Eye Problems on MedlinePlus
Diabetic Eye Problems trials in other cities
- San Antonio, TX4 studies
- San Francisco, CA3 studies
- Birmingham, AL3 studies
- Baltimore, MD3 studies
- Sacramento, CA3 studies
- Hagerstown, MD3 studies
- Austin, TX3 studies
- Bakersfield, CA3 studies
- Chicago, IL3 studies
- Carmel, IN3 studies
- Raleigh, NC3 studies
- Glendale, CA3 studies
Other studies in Houston
- Non-Small Cell Lung Cancer143 studies
- Breast Cancer126 studies
- Cancer (all types)124 studies
- Colorectal Cancer101 studies
- Metastatic Cancer100 studies
- Ovarian Cancer90 studies
- Acute Myeloid Leukemia88 studies
- Lung Cancer78 studies
- Prostate Cancer73 studies
- Endometrial Cancer69 studies
- Melanoma61 studies
- Pancreatic Cancer59 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.